Function analysis of CD4+ and CD8+T lymphocytes in peripheral blood of children with EB virus infection-related liver damage

Abstract

Abstract: Objective To evaluate the function of CD4⁺ and CD8⁺ T lymphocytes in peripheral blood of children with EB virus infection-related liver damage. Methods 104 cases of children infected with EB virus between January 2022 and June 2024 in our hospital were divided into liver damage group and non-liver damage group according to whether they were complicated with liver damage or not. The general data, CD4⁺, CD8⁺ T lymphocyte subsets and their surface markers expression levels in peripheral blood of the two groups were compared before and after treatment. Results There were 43 cases with liver damage and 61 cases without liver damage in 104 children. The levels of ALT, AST and TBil in the liver damage group were (56.3±17.3) U/L, (50.2±15.5) U/L and (23.2±4.3) μmol/L, which were significantly higher than those in the non-liver damage group [(35.6±11.0) U/L, (35.1±9.7) U/L, (15.2±2.4) μmol/L, P<0.05]. After treatment, the ratio of CD4⁺ T lymphocytes and CD4⁺/CD8⁺ in the liver damage group were (36.7±3.6)% and (1.2±0.2), which were significantly higher than those in the non-liver damage group [(34.7±3.2)% and (1.1±0.4), respectively, P<0.05]. The expression percentages of CD45RA, CD45RO, CCR3 and CD28 on the surface of CD4⁺ T lymphocytes in liver damage group were 21.2 (16.3, 24.4)%, 19.0 (14.5, 23.2)%, 15.1 (8.9, 23.8)% and 42.3 (36.2, 52.7)%, they were significantly higher than those in the non-liver damage group [18.2 (14.3, 23.5)%, 13.7 (9.3, 17.2)%, 8.1 (4.0, 10.3)% and 33.6 (30.3, 38.4)%, P<0.05]. The expression percentages of CD45RA, CCR3 and CD25 on the surface of CD8⁺ T lymphocytes in liver damage group were 17.3 (13.4, 19.7)%, 1.1 (0.5, 2.6)% and 0.6 (0.3, 1.0)%, they were significantly higher than those in the non-liver damage group [13.9 (9.6, 17.1)%, 0.7 (0.4, 0.9)% and 0.3 (0.2, 0.4)%] (P<0.05). Conclusion The imbalance of CD4⁺ and CD8⁺ cells in peripheral blood and the abnormal expression of cell surface markers in children with EB virus infection complicated with liver damage may affect the clinical outcome of patients, whichdeserves further study.

Key words: EB virus infection, Liver damage, Lymphocyte function, Immunologic function

CAI Xin, CHEN Zheng-xu, YUAN Run-lin, CHAI Ye. Function analysis of CD4⁺ and CD8⁺T lymphocytes in peripheral blood of children with EB virus infection-related liver damage[J]. Chinese Hepatolgy, 2025, 30(5): 705-708.

References

[1] Gao W, Wu J, Han Y, et al. Study on diagnostic value of results of EB virus nucleic acid quantification in whole blood lymphocyte and serum in children with EB virus infection[J]. Cytokine, 2022, 155:155902.
[2] Hao G, Jiang L, Wen L, et al. Clinical laboratory analysis of EB virus associated hemophagocytic lymphohistiocytosis in children[J]. Altern Ther Health Med, 2024, 30(5):148-154.
[3] 张蔷, 方庆丰, 杨志, 等. 传染性单核细胞增多症儿童外周血EB病毒DNA、IL-2及IL-6水平的检测价值分析[J]. 中国实验血液学杂志, 2022, 30(4):1262-1266.
[4] Naughton P, Enright F, Lucey B. Infectious mononucleosis: new concepts in clinical presentation, epidemiology, and host response[J]. Curr Opin Infect Dis, 2024, 37(3):157-163.
[5] Ming Y, Cheng S, Chen Z, et al. Infectious mononucleosis in children and differences in biomarker levels and other features between disease caused by Epstein-Barr virus and other pathogens: a single-center retrospective study in China[J]. PeerJ, 2023, 11:e15071.
[6] Páez-Guillán E M, Campos-Franco J, Alende R, et al. Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis[J]. Lipids Health Dis, 2021, 20(1):177.
[7] Jones R J, Seaman W T, Feng W H, et al. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease[J]. Int J Cancer, 2007, 121(6):1274-1281.
[8] Lemus Y B, Martínez G A, Lugo L P, et al. Gene profiling of epstein-barr virus and human endogenous retrovirus in peripheral blood mononuclear cells of SLE patients: immune response implications[J]. Sci Rep, 2024, 14(1):22032.
[9] Petrara M R, Cattelan A M, Zanchetta M, et al. Epstein-barr virus load and immune activation in human immunodeficiency virus type 1-infected patients[J]. J Clin Virol, 2012, 53(3):195-200.
[10] 全国儿童EB病毒感染协作组, 中华实验和临床病毒学杂志编辑委员会. EB病毒感染实验室诊断及临床应用专家共识[J]. 中华实验和临床病毒学杂志, 2018, 32(1):2-8.
[11] Chen T, Chen Y, Bao W, et al. T-lymphocyte subsets and Th1/Th2 cytokines in convalescent patients with Epstein-Barr virus-associated aplastic anemia[J]. Hematology, 2020, 25(1):11-16.
[12] Mautner J, Bornkamm G W. The role of virus-specific CD4⁺ T cells in the control of Epstein-Barr virus infection[J]. Eur J Cell Biol, 2012, 91(1):31-35.
[13] Ressing M E, Horst D, Griffin B D, et al. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products[J]. Semin Cancer Biol, 2008, 18(6):397-408.
[14] Kalra M, Gerdemann U, Luu J D, et al. Epstein-barr virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy[J]. Cytotherapy, 2019, 21(2):212-223.
[15] Yang C, Zhu X, Zhang T, et al. EBV-HLH children with reductions in CD4⁺ T cells and excessive activation of CD8⁺ T cells[J]. Pediatr Res, 2017, 82(6):952-957.
[16] Ahmed MGT, Limmer A, Hartmann M. CD45RA and CD45RO are regulated in a cell-type specific manner in inflammation and sepsis[J]. Cells, 2023, 12(14):1873.
[17] Yang W, Jia X, Su Y, et al. Immunophenotypic characterization of CD45RO⁺ and CD45RA⁺ T cell subsets in peripheral blood of peripheral T cell lymphoma patients[J]. Cell Biochem Biophys, 2014, 70(2):993-997.
[18] Dai M, Zhu X, Yu J, et al. CCR3 gene knockout in bone marrow cells ameliorates combined allergic rhinitis and asthma syndrome (CARAS) by reducing airway inflammatory cell infiltration and Th2 cytokines expression in mice model[J]. Int Immunopharmacol, 2022, 104:108509.
[19] Pietruczuk M, Kraszula L, Kupczyk M, et al. Dynamics and proliferative capacities of CD8⁺CD28⁺TCRαβ⁺CD62L^high T-cell subsets in healthy and asthmatic subjects[J]. J Biol Regul Homeost Agents, 2021, 35(2):485-494.
[20] Arsenio J. Single-cell analysis of CD8 T lymphocyte diversity during adaptive immunity[J]. Wiley Interdiscip Rev Syst Biol Med, 2020, 12(2):e1475.

Function analysis of CD4⁺ and CD8⁺T lymphocytes in peripheral blood of children with EB virus infection-related liver damage

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Recommended Articles

Metrics

Comments

[1]	GU Ji, LI Rong-hua, ZHU Hai-yan, DONG Li. Therapeutic effect of transcatheter arterial chemoembolization combined with three-dimensional conformal radiation therapy on patients with advanced hepatitis B primary liver cancer [J]. Chinese Hepatolgy, 2025, 30(3): 366-370.
[2]	ZHONG Xiang-mei, WEI Li-jun. Analysis of the clinical efficacy and safety of doxycycline and azithromycin in patients with scrub typhus and hepatic damage [J]. Chinese Hepatolgy, 2025, 30(2): 253-257.
[3]	HE Guo-qing, CHU Kai-dong. Assessing the prognostic and diagnostic value of MLR, CD4⁺/CD8⁺ ratios, and APRI in children with infectious mononucleosis complicated by liver damage [J]. Chinese Hepatolgy, 2024, 29(5): 581-587.
[4]	DING Zhong-li, CUI Lei, CHU Kai-dong. Correlation of CAR and CD4⁺/CD8⁺ levels with disease severity and prognosis in children with infectious mononucleosis complicated with liver damage [J]. Chinese Hepatolgy, 2023, 28(5): 593-598.
[5]	DU Ting, YANG Yan, YANG Wen-jun, JIN Jing, SHENG Hui-ping. Analysis of pathological and clinical features of 128 cases of unexplained liver damage [J]. Chinese Hepatolgy, 2022, 27(3): 347-351.
[6]	LV Sa, ZHU Bing, XU Tian-jiao, LI Dong-ze, TIAN Hua, YOU Shao-li. The treatment mode of hyperthyroid patients with severe liver damage [J]. Chinese Hepatolgy, 2020, 25(11): 1212-1215.
[7]	SUN Jing, LIU Li-ying, YANG Xiao, ZHANG Ai-min, ZHANG Tao, WANG Jia, ZHANG Dan, DING Jun-qiang, LI Wen-gang, DUAN Xue-zhang. ICG R15 in the Prediction of the radiation-induced liver damage of stereotactic body radiotherapy in patients with hepato cellular carcinoma [J]. Chinese Hepatolgy, 2018, 23(11): 973-976.